CAS: 83435-66-9; Delapril

该化合物是一种主要用于治疗高血压和心脏衰竭的抗抑制剂(ACE),主要用于治疗高血压和心脏衰竭.作为一种治疗药物,它被转化成活性体,有助于放松血管和减少血压.Delapril的化学结构包括一个对药物活动至关重要的碳球酸组,其特点是它能够抑制将血管素I转换为血管素II,一种强大的血管抑制器,从而促进血管扩张和改善血液流动.Delapril通常通过口服方式进行,并因其相对有利的副作用而闻名于其他抗血压剂.常见副作用可能包括眩晕,疲劳和胃肠紊乱.与其他ACE抑制剂一样,它与其他AEC抑制剂一样,在有血管抑制治疗史的病人中是违反的,因此应该在肾脏损伤的个人中谨慎地使用.

结构式图片

MSDS等安全信息

    上下游产品

    delapril benzyl ester N-(2,3-dihydro-1 H-inden-2-yl)-glycine benzyl ester hydr°Chloride N-[1-(S)-(ethoxycarbonyl)-3-phenylpropyl]-L-alanine hydr°Chloride

    合成工艺路线路线简述

      Delapril Benzyl Ester置于盐酸,Palladium 10% On Activated Carbon,氢气体系中,用 乙醇,乙酸乙酯 作为反应溶剂,以91%的收率获得产物地拉普利
      参考文献: Process For The Preparation Of Amides Of N-[1-(S)-(Ethoxycarbonyl)-3-Phenylpropyl]-L-Alanine[fr] Procédé De Préparation D'Amides De N-[1-(S)-(éthoxycarbonyl)-3-Phénylpropyl]-L-Alanine
      标题: Process For The Preparation Of Amides Of N-[1-(S)-(Ethoxycarbonyl)-3-Phenylpropyl]-L-Alanine[fr] Procédé De Préparation D'Amides De N-[1-(S)-(éthoxycarbonyl)-3-Phénylpropyl]-L-Alanine
      摘要:描述了一种制备n-[1-(S)-(乙氧羰基)-3-苯基丙基]-L-丙氨酸酰胺的方法.该工艺可用于从n-[1-(S)-(乙氧羰基)-3-苯基丙基]-L-丙氨酸出发,通过与适当的胺类反应,生产关键中间体,最终生产ace抑制剂,如雷米普利,依那普利,喹那普利,群多普利,地拉普利和莫昔普利.

      海关参考信息

      专利信息


      专利号:US-9353057-B2
      优先权日:2003-12-30
      标 题:Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
      发明人:GALLOP MARK A; DAI XUEDONG; SCHEUERMAN RANDALL A; RAILLARD STEPHEN P; MANTHATI SURESH K; YAO FENMEI; PHAN THU; LUDWIKOW MARIA; PENG GE; BHAT SEEMA
      权利人:XENOPORT INC
      摘要:Methods for synthesis of 1-(acyloxy)-alkyl carbamates, particularly, the synthesis of 1-(acyloxy)-alkyl carbamate prodrugs of primary or secondary amine-containing drugs are described. Also described are methods for synthesis of 1-(acyloxy)-alkyl N-hydroxysuccinimidyl carbonates which are useful intermediates in the synthesis of 1-(acyloxy)-alkyl carbamates are also described.

      专利号:US-10925977-B2
      优先权日:2006-10-05
      标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
      发明人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S
      权利人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S; CEIL POINT LLC; UNIV TEXAS
      摘要:Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.

      专利号:US-10005720-B2
      优先权日:2013-04-05
      标题:Compounds useful for the treatment of metabolic disorders and synthesis of the same
      发明人:SEXTON JONATHAN Z; BRENMAN JAY E; MUSSO DAVID L
      权利人:NORTH CAROLINA CENTRAL UNIV; UNIV NORTH CAROLINA CHAPEL HILL
      摘要:The present invention provides compounds of Formula (I): wherein variables X, Y, Z and R1 are as described herein. Some of the compounds described herein are glutamate dehydrogenase activators. The invention is also directed to pharmaceutical compositions comprising these compounds, uses of these compounds and compositions in the treatment of metabolic disorders as well as synthesis of the compounds.

      专利号:US-7094920-B2
      优先权日:2001-05-21
      标 题 :Stereoselective synthesis of 2-hydroxy-4-phenylbutyric acid esters
      发明人:TIKARE RAVEENDRA KHANDURAO
      权利人:FERMENTA BIOTECH LTD
      摘要:A process is described for the stereospecific preparation of an ester of formula (I): wherein * signifies the (R) stereoisomer; R 1 is selected from C 1-6 alkyl, preferably ethyl; and R 2 is hydrogen, a protecting group or a leaving group which process comprises reaction of a nitrile of formula (II): wherein * signifies the (R) stereoisonomer; and Ph is the phenyl group C 6 H 5 with a solution of an inorganic acid in an alcohol and optional conversion of the compound of formula (I) wherein R 2 is H so prepared to any other desired compound of formula (I) by standard methods in the art. The compounds of formula (I) are chiral esters, useful as intermediates in the synthesis of the family of acetylcholine esterase (ACE) inhibitors known as “prilsâ€?, such as lisinopril, cilazapril, enalapril, benazepril, ramipril, delapril, enalaprilat, imidapril, spirapril, trandolapril and others.n n*n nPh-CH 2 —CH 2 —CH(OR 2 )—COOR 1   (I)n n*n nPh-CH 2 —CH 2 —CH(H)—CN  (II)

      专利号:US-8431712-B2
      优先权日:2004-02-09
      标 题 :Methods for the synthesis of pyridoxamine
      发明人:KHALIFAH RAJA G; KEILITZ ROLAND; KOELLNER CHRISTOPH; DEGENHARDT THORSTEN; BRAND STEPHEN ROBERT
      权利人:KHALIFAH RAJA G; KEILITZ ROLAND; KOELLNER CHRISTOPH; DEGENHARDT THORSTEN; BRAND STEPHEN ROBERT; NEPHROGENEX INC
      摘要:The invention provides non-oxidative methods for the large scale manufacture of pyridoxamine (I) (4-aminomethyl-3-hydroxy-5-hydroxymethyl-2-methylpyridine): n nand salts thereof.n nThe invention also provides intermediate compounds for the synthesis of pyridoxamine, as well as compositions and methods for the treatment and/or prevention of conditions associated with the formation of post-Amadori advanced glycation end-products.

      专利号:US-2003050305-A1
      优先权日:2000-05-22
      标题:Thromboxane inhibitors, compositions and methods of use
      发明人:TEJADA INIGO SAENZ DE
      摘要:The present invention describes methods for treating or preventing sexual dysfunctions in males and females, and for enhancing sexual responses in males and females by administering a therapeutically effective amount of at least one thromboxane inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase, and/or at least one vasoactive agent. The male or female may preferably be diabetic. The present invention also provides novel compositions comprising at least one thromboxane inhibitor, and, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase, and, optionally, at least one therapeutic agent, such as, vasoactive agents, nonsteroidal antiinflanmmatory compounds (NSAIDs), selective cyclooxygenase-2 (COX-2) inhibitors, anticoagulants, angiotensin converting enzymes (ACE) inhibitors, angiotensin II receptor antagonists, renin inhibitors, and mixtures thereof. The present invention also provides methods for treating or preventing ischemic heart disorders, myocardial infarction, angina pectoris, stroke, migraine, cerebral hemorrhage, cardiac fatalities, transient ischaemic attacks, complications following organ transplants, coronary artery bypasses, angioplasty, endarterectomy, atherosclerosis, pulmonary embolism, bronchial asthma, bronchitis, pneumonia, circulatory shock of various organs, nephritis, graft rejection, cancerous metastases, pregnancy-induced hypertension, preeclampsia, eclampsia, thrombotic and thromboembolic disorders, intrauterine growth, gastrointestinal disorders, renal diseases and disorders, disorders resulting from elevated uric acid levels and dysmenorrhea, and for inhibiting platelet aggregation or platelet adhesion or relaxing smooth muscles.
      成都奥森生物技术有限公司
      ⚠️ 未注册 · 未认证企业
      ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
      数据来源于公开网络搜索,平台未作核实,请自行辨别。
      🏢敬请 企业认领
      🏬开设公司展台
      📢获取免费会员权益
      🎖️点亮专属注册企业标签
      📇展现公司完整信息 样本查看立即注册认领 →
      电话:028-85523158👤
      ⚠️参考联系方式
      联系电话:028-85523158
      传真号码: 028-85523158
      🆔 联系时候可告知是从"百琢研"平台获取的信息.
      ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

      成都市一环路南四段16号
      ⚠️ 未注册 · 未认证企业
      注册入口 声明: 数据来源:本内容基于各搜索引擎等公开数据整理,仅作展示用。请自行辨别 📄若企业需抹除相关内容或, 请联系方我们,我们即刻栓除。
      北京东方德众科技发展有限公司
      ⚠️ 未注册 · 未认证企业
      ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
      数据来源于公开网络搜索,平台未作核实,请自行辨别。
      🏢敬请 企业认领
      🏬开设公司展台
      📢获取免费会员权益
      🎖️点亮专属注册企业标签
      📇展现公司完整信息 样本查看立即注册认领 →
      电话:010-89282319👤
      ⚠️参考联系方式
      邮件:dfdz@dfdzchem.com
      联系电话:010-89282319
      手机号码: 13801117689
      传真号码: 010-89282979
      北京市大兴区庞各庄镇隆盛园物业楼2-3层
      🆔 联系时候可告知是从"百琢研"平台获取的信息.
      ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

      北京市大兴区庞各庄镇隆盛园物业楼2-3层
      ⚠️ 未注册 · 未认证企业
      注册入口 声明: 数据来源:本内容基于各搜索引擎等公开数据整理,仅作展示用。请自行辨别 📄若企业需抹除相关内容或, 请联系方我们,我们即刻栓除。
      第 1 / 1 页
      现货

      供应商参考报价(招募中)

      品牌试剂参考报价(招募中)

      📌 第三方产品分析报告

      ✅ COA系统入驻 | 共享模式

      主要参考文献


      1: González-Juanatey JR, Cordero A. Benefits of delapril in hypertensive patients along the cardiovascular continuum. Expert Rev Cardiovasc Ther. 2013 Mar;11(3):271-81. doi: 10.1586/erc.12.188. 27(6):367-80. doi: 10.2165/00044011-200727060-00001. 66(7):961-9. doi: 10.2165/00003495-200666070-00014. 31(7):439-53. doi: 10.2165/11589000-000000000-00000. 75(18):7F-12F. doi: 10.1016/s0002-9149(99)80508-6. 3(3):255-63.
      7: Kahan T, Ambrosioni E. Delapril/manidipine: viewpoints. Drugs. 2006;66(7):970-1. doi: 10.2165/00003495-200666070-00016. 5(2):147-59. doi: 10.1586/14779072.5.2.147. 4(1 Pt 2):23S-28S. doi: 10.1093/ajh/4.1.23s. 47(2):97-104. doi: 10.1016/s0168-8227(99)00114-x. 41(1):74-9. doi: 10.1038/clpt.1987.12. 15(7):642-51. doi: 10.2174/1566524015666150831131459. 18(10):687-91. doi: 10.1038/sj.jhh.1001726. 47(5):361-6. doi: 10.2169/internalmedicine.47.0449. Epub 2008 Mar 3. 26(9):1419-26. doi: 10.1016/j.clinthera.2004.09.018. 33(1):43-51. doi: 10.1016/0168-8227(96)01273-9. 36(3):321-8. doi: 10.1097/00005344-200009000-00007. 4(1 Pt 2):60S-66S. doi: 10.1093/ajh/4.1.60s. 4(1 Pt 2):42S-45S. doi: 10.1093/ajh/4.1.42s. 17(3):287-96. doi: 10.1255/ejms.1128.

      合成参考文献


      参考文献:10.2165/00003495-199651050-00006
      摘要:Wagstaff AJ, Davis R, McTavish D. Fosinopril: a reappraisal of its pharmacology and therapeutic efficacy in essential hypertension. Drugs. 1996 May;51(5):777–91. doi: 10.2165/00003495-199651050-00006.
      参考文献:10.2165/00002018-199615010-00006
      摘要:Overlack A. ACE inhibitor-induced cough and bronchospasm. Incidence, mechanisms and management. Drug Saf. 1996 Jul;15(1):72–8. doi: 10.2165/00002018-199615010-00006.
      📝 需求与反馈
      尽可能描述清楚需求与问题信息
      ×

      通知